Beta
310636

CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas

Article

Last updated: 01 Jan 2025

Subjects

-

Tags

Pathology

Abstract

BACKGROUND: The basis of cancer management is understanding its underlying molecular abnormalities. To improve survival of ovarian cancer patients, new therapeutic targets and prognostic markers are needed. SMYD3 and CDK9 are two markers that play important role in epigenetic regulation and promotion of oncogenic process. They have to be under investigation to be used as target for therapy. Objective: evaluation the diagnostic and prognostic value of the immunohistochemical expression of SMYD3 and CDK9 in serous ovarian carcinoma (SOC). Methods: 50 cases of SOC and 50 benign ovarian lesions cases were included in this study. The morphological classification was assessed according to the World Health Organization criteria. Immunohistochemistry (IHC) for CDK9 and SMYD3 was performed. Results: SMYD3 and CDK9 was highly expressed in cancer compared with benign lesions (p <0.001 and <0.05 respectively). High CDK9 and SMYD3 expression were significantly associated with vascular invasion and advanced stage disease (p <0.001 for both). Patients who exhibited high SMYD3 and CKD9 expression showed poor treatment response, drug resistance and higher frequency of relapse and mortality. Conclusions: The immunohistochemical staining of SMYD3 and CDK9 is higher in serous ovarian carcinoma compared with benign ovarian lesions and represents a worse prognostic factor.

DOI

10.21608/zumj.2023.216665.2811

Keywords

SMYD3, CDK9, serous ovarian carcinomas, prognosis, Immunohistochemistry

Authors

First Name

mona

Last Name

mostafa

MiddleName

-

Affiliation

Zagazig university

Email

mostafamona90@yahoo.com

City

-

Orcid

0000-0003-2149-5439

First Name

Amr

Last Name

Awd

MiddleName

A.

Affiliation

Obstetrics and Gynecology , Faculty of medicine, Zagazig University

Email

amrawd75@yahoo.com

City

-

Orcid

-

First Name

Amira

Last Name

Elwan

MiddleName

-

Affiliation

Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Egypt

Email

essawy1951@gmail.com

City

zagazig

Orcid

0000-0003-2464-5113

First Name

DALIA

Last Name

ELSAYED

MiddleName

HAMOUDA

Affiliation

MEDICAL ONCOLOGY FACULTY OF MEDICINE ZAGAZIG UNIVERSITY

Email

hamoudadg@gmail.com

City

-

Orcid

-

First Name

Sabah

Last Name

Hanafy

MiddleName

mohamed

Affiliation

pathology department

Email

drsabahmohamed@gmail.com

City

zagazig

Orcid

-

Volume

29

Article Issue

6

Related Issue

44286

Issue Date

2023-11-01

Receive Date

2023-06-14

Publish Date

2023-11-01

Page Start

1,497

Page End

1,505

Print ISSN

1110-1431

Online ISSN

2357-0717

Link

https://zumj.journals.ekb.eg/article_310636.html

Detail API

https://zumj.journals.ekb.eg/service?article_code=310636

Order

310,636

Type

Original Article

Type Code

273

Publication Type

Journal

Publication Title

Zagazig University Medical Journal

Publication Link

https://zumj.journals.ekb.eg/

MainTitle

CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas

Details

Type

Article

Created At

30 Dec 2024